Stable Istotope Labelled Tarextumab Biosimilar – Anti-CD52 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Istotope Labelled Tarextumab Biosimilar - Anti-CD52 mAb - Research Grade |
|---|---|
| Source | CAS 1359940-55-8 |
| Species | Caninized |
| Expression system | Mammalian cells |
| Purity | >95% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue Ice |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | OMP-59R5 |
| Reference | PX-TA1326-SIL |
| Related Products | PX-P4074 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG2-kappa-lambda |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
General information on Anti-CD52[Homo sapiens] (Tarextumab) Monoclonal Antibody
Tarextumab has beeninvestigated for the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
Contact us
Send us a message from the form below
Reviews
There are no reviews yet.